Limits...
Advances in treating chronic lymphocytic leukemia.

Tausch E, Mertens D, Stilgenbauer S - F1000Prime Rep (2014)

Bottom Line: Chronic lymphocytic leukemia (CLL) is the most prevalent type of leukemia, affects mostly elderly CLL patients, and is incurable without allogeneic transplantation.Although classic chemo(immuno)therapy is still the standard of care for patients in need of treatment, this paradigm might change in the near future with the advent of new therapeutic agents targeting major pathogenic pathways in CLL.

View Article: PubMed Central - PubMed

Affiliation: Ulm University, Department of Internal Medicine III Albert-Einstein-Allee 23, 89081 Ulm Germany.

ABSTRACT
Chronic lymphocytic leukemia (CLL) is the most prevalent type of leukemia, affects mostly elderly CLL patients, and is incurable without allogeneic transplantation. Although classic chemo(immuno)therapy is still the standard of care for patients in need of treatment, this paradigm might change in the near future with the advent of new therapeutic agents targeting major pathogenic pathways in CLL.

No MeSH data available.


Related in: MedlinePlus

New therapeutic agents and their targets in a chronic lymphocytic leukemia cellBCL2, B-cell lymphoma 2; BCR, B-cell receptor; BTK, Bruton's tyrosine kinase; NFκB, nuclear factor kappa B; PI3K, phophoinositide 3-kinase; PKC, protein kinase C; PLC, phospholipase C.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4126532&req=5

fig-001: New therapeutic agents and their targets in a chronic lymphocytic leukemia cellBCL2, B-cell lymphoma 2; BCR, B-cell receptor; BTK, Bruton's tyrosine kinase; NFκB, nuclear factor kappa B; PI3K, phophoinositide 3-kinase; PKC, protein kinase C; PLC, phospholipase C.

Mentions: With more than 15,000 newly diagnosed cases in the US in 2012, CLL is the most common leukemia in the Western world and affects mainly elderly patients [1]. Different manifestation patterns and a wide range of genetic variations like hypermutation of the immunoglobulin heavy-chain genes (IGHV), genomic aberrations, and recurrent gene mutations in oncogenes and tumor suppressor genes reflect the clinical and biological heterogeneity of the disease [2,3]. CLL is still incurable without allogeneic stem cell transplantation, although treatment outcome has considerably improved by using risk stratification and novel therapeutic agents [4,5]. This article gives an overview of classic treatments and new compounds in clinical use. First, we cover traditional treatment with chemoimmunotherapy, and then we highlight key features of novel agents (see also Figure 1).


Advances in treating chronic lymphocytic leukemia.

Tausch E, Mertens D, Stilgenbauer S - F1000Prime Rep (2014)

New therapeutic agents and their targets in a chronic lymphocytic leukemia cellBCL2, B-cell lymphoma 2; BCR, B-cell receptor; BTK, Bruton's tyrosine kinase; NFκB, nuclear factor kappa B; PI3K, phophoinositide 3-kinase; PKC, protein kinase C; PLC, phospholipase C.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4126532&req=5

fig-001: New therapeutic agents and their targets in a chronic lymphocytic leukemia cellBCL2, B-cell lymphoma 2; BCR, B-cell receptor; BTK, Bruton's tyrosine kinase; NFκB, nuclear factor kappa B; PI3K, phophoinositide 3-kinase; PKC, protein kinase C; PLC, phospholipase C.
Mentions: With more than 15,000 newly diagnosed cases in the US in 2012, CLL is the most common leukemia in the Western world and affects mainly elderly patients [1]. Different manifestation patterns and a wide range of genetic variations like hypermutation of the immunoglobulin heavy-chain genes (IGHV), genomic aberrations, and recurrent gene mutations in oncogenes and tumor suppressor genes reflect the clinical and biological heterogeneity of the disease [2,3]. CLL is still incurable without allogeneic stem cell transplantation, although treatment outcome has considerably improved by using risk stratification and novel therapeutic agents [4,5]. This article gives an overview of classic treatments and new compounds in clinical use. First, we cover traditional treatment with chemoimmunotherapy, and then we highlight key features of novel agents (see also Figure 1).

Bottom Line: Chronic lymphocytic leukemia (CLL) is the most prevalent type of leukemia, affects mostly elderly CLL patients, and is incurable without allogeneic transplantation.Although classic chemo(immuno)therapy is still the standard of care for patients in need of treatment, this paradigm might change in the near future with the advent of new therapeutic agents targeting major pathogenic pathways in CLL.

View Article: PubMed Central - PubMed

Affiliation: Ulm University, Department of Internal Medicine III Albert-Einstein-Allee 23, 89081 Ulm Germany.

ABSTRACT
Chronic lymphocytic leukemia (CLL) is the most prevalent type of leukemia, affects mostly elderly CLL patients, and is incurable without allogeneic transplantation. Although classic chemo(immuno)therapy is still the standard of care for patients in need of treatment, this paradigm might change in the near future with the advent of new therapeutic agents targeting major pathogenic pathways in CLL.

No MeSH data available.


Related in: MedlinePlus